Cancer Immunol Immunother (2006)
DOI 10.1007/s00262-006-0123-0

ORIGINAL ARTICLE

Kousaku Mimura · Koji Kono · Scott Southwood
John Fikes · Akihiro Takahashi · Naoto Miyagawa
Hidemitsu Sugai · Hideki Fujii

Substitution analog peptide derived from HER-2 can efficiently induce HER-2-specific, HLA-A24 restricted CTLs

Received: 18 October 2005 / Accepted: 30 December 2005
© Springer-Verlag 2006

Abstract In order to broaden the possibility for anti-HER-2/neu (HER-2) immune targeting, it is important to identify HLA-A24 restricted peptide epitopes derived from HER-2, since HLA-A24 is one of the most common alleles in Japanese and Asian people. In the present study, we have screened HER-2-derived, HLA-A24 binding peptides for cytotoxic T lymphocyte (CTL) epitopes. A panel of HER-2-derived peptides with HLA-A24 binding motifs and the corresponding analogs designed to enhance HLA-A24 binding affinity were selected. Identification of HER-2-reactive and HLA-A24 restricted CTL epitopes were performed by a reverse immunology approach. To induce HER-2-reactive and HLA-A24 restricted CTLs, PBMCs from healthy donors were repeatedly stimulated with monocytes-derived, mature DCs pulsed with HER-2 peptide. Subsequent peptide-induced T cells were tested for the specificity by enzyme linked immunospot, cytotoxicity and tetramer assays. CTL clones were then obtained from the CTL lines by limiting dilution. Of the peptides containing HLA-A24 binding motifs, 16 peptides (nine mers) including wild type peptides ($IC_{50} < 1{,}000$ nM) and substituted analog peptides ($IC_{50} < 50$ nM) were selected for the present study. Our studies show that an analog peptide, HER-2(905AA), derived from HER-2(905) could efficiently induce HER-2-reactive and HLA-A24 restricted CTLs. The reactivity of the HER-2(905AA)-induced CTL (CTL905AA) was confirmed by different CTL assays. The CTL905AA clones also were able to lyse HER-2(+), HLA-A24(+) tumor cells and cytotoxicity could be significantly reduced in cold target inhibition assays using cold targets pulsed with the HER-2(905) wild type peptide as well as the inducing HER-2(905AA) analog peptide. A newly identified HER-2(905) peptide epitope is naturally processed and presented as a CTL epitope on HER-2 overexpressing tumor cells, and an MHC anchor-substituted analog, HER-2(905AA), can efficiently induce HER-2-specific, HLA-A24 restricted CTLs.

Keywords Substitution analog · HLA-A24 · HER-2 · Epitope · CTL

K. Mimura · K. Kono (✉) · A. Takahashi · N. Miyagawa
H. Sugai · H. Fujii
First Department of Surgery, University of Yamanashi,
1110 Tamaho, 409-3898 Yamanashi, Japan
E-mail: kojikono@yamanashi.ac.jp
Tel.: +81-552-736751
Fax: +81-552-739574

S. Southwood · J. Fikes
Epimmune, Inc., San Diego, CA 92121, USA

Introduction

It is now well established that small peptide epitopes which bind to MHC class I molecules on the surface of tumor cells can be recognized as antigens (Ags) by cytotoxic T lymphocyte (CTL). Tumor-specific CTL, adoptively transferred or activated in vivo by tumor-associated CTL epitopes, have therapeutic activity and can induce regression of established tumors or micrometastases [23, 27]. The development of immunotherapeutic methods to treat cancer is critically dependent on the identification of tumor-associated Ags. Several immunogenic peptide epitopes, recognized by CTL lines and clones, have been defined from human carcinomas [1, 4, 6, 11, 12, 33].

As an alternative to the genetic and biochemical approach for identifying tumor-associated CTL epitopes, a reverse immunology method has been developed [2, 12, 13, 34]. In this method, predicted MHC class I binding epitopes within a tumor Ag sequence are identified using algorithms of MHC anchor residue motifs and peptides corresponding to these epitopes are synthesized and tested to confirm binding to purified HLA molecules. Peptides demonstrating strong HLA binding affinity are screened further for their capacity to induce peptide- and tumor-specific CTL from healthy individuals or cancer patients. This approach has recently been used for the definition of several new CTL epitopes in different

melanoma Ags [2, 12, 13, 34] as well as tumor Ags expressed on breast, colon and lung adenocarcinomas [15].

The HER-2/neu (HER-2) proto-oncogene encodes a 185-kDa transmembrane glycoprotein that contains an extracellular domain and an intracellular domain with tyrosine-specific kinase activity and has a similarity in structure and sequence to the epidermal growth-factor receptor [5]. HER-2 is amplified and overexpressed in approximately 30% of the human ovarian and breast tumors [29], and in 20% of gastric cancers [10], and is correlated with the stage progression of gastric cancer [19, 30]. In a previous study, we have provided evidence that HER-2-derived peptides are naturally processed as tumor-associated Ags in gastric cancer and can be recognized by tumor-specific, HLA-A2 restricted CTLs [18]. HLA-A2 restricted CTL epitopes derived from HER-2, that are recognized by ovarian [8, 17] and breast [22] cancer-specific CTLs, have previously been defined. Additional HLA-A2 restricted, CTL epitopes derived from HER-2 which can activate CTLs from healthy donors and patients with advanced ovarian carcinoma have also been reported [14, 26]. Based on the above reports, it may be speculated that anti-HER-2 immune targeting may be utilized as a common approach to immunotherapy of a variety of cancers.

HLA-A24 is one of the most common alleles in the Japanese population with more than 60% of this ethnic group expressing this HLA allele [7]. Therefore, in order to broaden the possibility for anti-HER-2 immune targeting, it is important to identify HLA-A24 restricted peptide epitopes derived from HER-2. Furthermore, in this study, we have synthesized analogs of HER-2-derived peptides which are substituted at one or both of the MHC anchor positions of the sequence to enhance HLA binding and immunogenicity. It has been shown that MHC anchor-substituted analogs derived from gp100 can more efficiently induce CTL response than wild type peptide epitopes [25].

In the present study, we describe the identification of a new HLA-A24 restricted, HER-2-derived anchor-substituted analog epitope which efficiently induces CTLs that respond to the native HER-2 wild type peptide epitope as well as to the endogenously processed epitope presented by HLA-A24(+) and HER-2(+) tumor cell lines.

Material and methods

Cell lines

MKN-7 (HER-2+, HLA-A26+ gastric cancer), KATOIII (HER-2+, HLA-A24+ gastric cancer), MRKnu-1 (HER-2+, HLA-A24+ gastric cancer), WiDr (HER-2+, HLA-A24+ colon cancer) and PC-9 (HER-2+, HLA-A24+ lung cancer) were obtained from the IBL cell bank (Gunma, Japan). HCT-15 (HER-2+, HLA-A24+ colon cancer), SKOV 3 (HER-2+, HLA-A3/A11+ ovarian cancer) and K562 (HER-2−, HLA-A24− lymphoma cell) were obtained from ATCC (Rockville, MD). TISI cells are human B-lymphoblastoid cell lines expressing HLA-A24. These cell lines were kept in RPMI 1640 with 5% FCS, 50 U/ml penicillin and 2 mM L-glutamine.

Peptide synthesis

Peptides were either synthesized at Epimmune, Inc. (San Diego, CA), as previously described [28], or, for large epitope libraries, purchased as crude material from Mimotopes (Clayton, Victoria, Australia). Peptides synthesized at Epimmune were purified to >95% homogeneity by reverse-phase HPLC. Purity was determined on an analytical reverse-phase column and the composition was ascertained by amino acid analysis and/or mass spectrometry analysis. In the present study, we have synthesized HER-2-derived peptides with HLA-A24 binding motifs and the corresponding analogs designed to enhance HLA-A24 binding affinity.

HLA-A24 binding assay

The peptide binding assay specific for HLA-A24 molecules has been described previously [16, 21]. Briefly, the assay is based on the inhibition of a radiolabeled standard peptide to detergent solubilized HLA molecules by unlabeled test peptides. The standard peptide, with the sequence AYIDNYNKF, was radiolabeled with ^{125}I by the chloramine T method. HLA-A24 molecules were purified by affinity chromatography from detergent extracts prepared from the EBV-transformed cell line KT3, as previously described [16]. Purified human HLA-A*2402 molecules, at a concentration which bound approximately 10–20% of the total radioactivity (generally between 5 and 15 nM), were incubated with 1–10 nM of the ^{125}I-radiolabeled probe peptide and varying doses of test peptide ranging from 120 μg/ml to 1.2 ng/ml. The binding reaction between HLA molecules, standard peptide and the competing test peptide was carried out in the presence of 1 μM human β_2-microglobulin (Scripps Laboratories, San Diego, CA) and a cocktail of protease inhibitors for 48 h at room temperature. Class I peptide complexes were then separated from the free peptide by gel filtration on TSK2000 columns (Tosohaus, Montgomeryville, AL). Peptide binding was quantified by determining the concentration of peptide required to inhibit the binding of the radiolabeled standard peptide by 50% (IC_{50}%). Peptides were tested in 2–4 independent experiments. The average IC_{50} level of the standard peptide was 6.0 nM.

Preparation of DCs

DCs were generated from PBMC from HLA-A24 healthy donors. Briefly, PBMCs were separated from

peripheral blood by centrifugation over Ficoll-Paque (Pharmacia, Uppsala, Sweden) and monocytes were enriched by adherence to a plastic tissue culture flask (Corning, NY) for 90 min at 37°C. Adherent cells were cultured with 1,000 units/ml of granulocyte macrophage colony-stimulating factor (GM-CSF, Peprotech EC Ltd, London, UK) and 1,000 units/ml of IL-4 (Peprotech EC Ltd) in X-VIVO (Life Technologies, Inc., Gaithersburg, MD). On day 5, the DCs were matured with TNF-alpha (10 ng/ml, Peprotech EC Ltd), PGE_2 (1 µg/ml), IL-1β (10 ng/ml), IL-6 (1,000 U/ml). On day 7, the cytokine-treated cells were used as mature DC.

Generation of HER-2-specific CTL lines and CTL clone

After 7 days of culture as described above, mature DCs were pulsed with HER-2 peptide (20 µg/ml), which included the wild type peptide and the substitution analog peptide, in the presence of β_2-microglobulin (3 µg/ml) for 60 min at 37°C. Then, these peptide (wild type or substitution analog)-loaded mature DCs were co-incubated with autologous PBMCs, which were obtained from HLA-A24 healthy donors, at 1:10 in a 12-well plate in X-VIVO with 1% autologous serum, 100 IU/ml of IL-2 (Shionogi). Subsequent cultured cells were restimulated with these peptide-loaded, irradiated (25 Gy) mature DCs every 7 days. After four stimulations, the cultured CTL lines were tested for the reactivity with the enzyme linked immunospot (Elispot) analysis and cytotoxic assay. All CTL lines were generated from five different healthy donors.

CTL clone was then obtained from the CTL lines by limiting dilution. Briefly, the CTLs were isolated in 96-well U-bottom plates in X-VIVO with irradiated allogeneic PBMC (5×10^4 cells/well) from two different donors in the presence of HER-2 peptide (20 µg/ml) and 100 IU/ml of IL-2 (Shionogi). The CTL clones were expanded with irradiated allogeneic PBMC, HER-2 peptide and 100 IU/ml of IL-2.

Elispot analysis and cytotoxic assay

The HER-2-specific response was determined by the IFN-γ Elispot analysis and cytotoxic assay. Elispot analysis was performed with the Mabtech assay system (Nacka, Sweden). After 96-well plates with nitrocellulose membrane (Millipore) were pre-coated with a primary anti-IFN-γ antibody (1D1K) for 24 h, the plates were pre-treated with AIM-V containing 1% human serum albumin. Target cells (2×10^4 per well) and CTLs (2×10^3 per well) were incubated in 200 µl of AIM-V for 24 h in triplicate. Thereafter, a biotinylated secondary anti-IFN-γ antibody (7-B6-1) was added for 2 h and then the plates were incubated with the streptavidin-alkaline phosphatase reagent and stained with NBT and BCIP (Gibco). All Elispot analyses were performed in the same condition.

For the cytotoxic assay, a standard 4 h ^{51}Cr release assay was performed. To assess the peptide-specificity of CTL, TISI cells were pulsed with HER-2-derived, HLA-A24 restricted peptide for 16 h at 37°C. Thereafter, peptide-pulsed TISI cells were washed and subjected to the cytotoxic assay as a target. After the target cells were labeled with 100 µCi ^{51}Cr for 60 min, they (5×10^3 per well) and the effector cells at various effector/target ratios were co-incubated in 200 µl of X-VIVO medium in a 96-well U-bottom plate in triplicate for 4 h at 37°C. Subsequently, cold target inhibition was carried out using the non-radiolabeled TISI cells loaded with HER-2 peptide or with an irrelevant HIV peptide (as negative control) at various hot/cold target ratios. The supernatants were harvested and radioactivity was determined using a gamma counter. The percentage of ^{51}Cr release was calculated according to the following formula: $\%\text{lysis} = 100 \times$ (experimental release − spontaneous release)/(maximum release − spontaneous release).

Flow cytometric analysis and tetramer assay

For the evaluation of HER-2 expression, a PE-labeled anti-HER-2 mAb (Becton Dickinson, San Jose, CA) and PE-labeled mouse IgG1 mAb (Beckman-Coulter, Miami, FL) as a negative control were used for immunostaining by flow cytometric analysis.

To evaluate the specificity of the CTL905AA clone, FITC-labeled anti-CD8 (MBL, Nagoya, Japan) and a PE-labeled HLA-A*2402-HER-2(905AA) tetramer (NH_2–VYSYGVTVF–COOH:905AA peptide; MBL, Nagoya, Japan) were used for immunostaining, according to the manufacturer's recommendations.

Statistics

To evaluate statistical differences between the two groups, a non-paired Student's t test was performed. Statistically significant differences were considered to be P values < 0.05.

Results

Identification of HLA-A*2402 binding epitopes and generation of HER-2-derived, epitope-specific CTL lines

HER-2-derived epitopes were identified on the basis of the presence of an HLA-A2402 binding motif by scanning the HER-2 protein with a customized computer program which accounts for both primary and secondary HLA binding anchor residues contained within the HLA-A24 epitopes [16, 21]. In addition to the identified wild type peptides, sequences possessing suboptimal residues at anchor positions were modified to enhance the binding capacity for HLA-A*2402 molecules. Preferred anchor residues for A*2402 have been deter-

mined by Epimmune and others [21] to be tyrosine (Y) at position 2 and phenylalanine (F) at the carboxy terminus. In the present study, nineteen nonamers carrying the HLA-A24 binding motif were selected, including ten wild type peptides (IC_{50} < 1,000 nM) and nine substitution analog peptides (IC_{50} < 50 nM; Table 1). All of the substitution analog peptides showed a high binding affinity for HLA-A24 (IC_{50} < 50 nM), while wild type peptides showed a range of affinity from high to weakly intermediate.

Of these peptides, we excluded the already known peptide epitopes HER-2(8), HER-2(780) and HER-2(63) [9, 24, 31], and generated 16 different peptide-specific CTL lines from five different HLA-A24(+) healthy donors by using mature DC cells pulsed with each of the remaining peptides. Then, the CTL lines were tested for their specificity against the cognate peptide used for each CTL induction, in an Elispot analysis. The reactivities of the peptide-induced CTL lines are shown in Fig. 1. In the present study, each peptide was considered positive if the spot forming cells (SFC) against TISI targets pulsed with cognate peptide was more than twofold SFC against CTL only in an Elispot analysis. Three CTL lines (CTL780A, CTL905AA and CTL414AA induced by the HER-2(780A), HER-2(905AA) and HER-2(414AA) epitopes, respectively) out of the 16 T cell lines significantly recognized TISI targets pulsed with each inducing cognate peptide.

HER-2 peptide-specific CTL lines can specifically recognize HLA-A24 tumor cell lines overexpressing HER-2

The CTL780A, CTL905AA and CTL414AA lines, wherein each CTL line was generated from five different healthy donors, were tested against HER-2-expressing tumor cell lines in an Elispot analysis. In the present study, the response of the CTL line against the tumor cell line was positive if the SFC against HLA-A24 positive, HER-2 positive tumor cell line was more than threefold SFC against HLA-A24 negative, HER-2 positive tumor cell line in an Elispot analysis. Out of the three CTL lines, only the CTL 905AA line recognized HLA-A24 positive tumor cell lines overexpressing HER-2 (PC-9 and HCT-15), but not a HLA-A24 negative HER-2 positive MKN-7 tumor cell line (Fig. 2). To further confirm the reactivity, CTL 905AA lines, which were generated from five different healthy donors, were tested against several targets in a cytotoxicity assay. The CTL 905AA line lysed HER-2(+), HLA-A24(+) HCT-15 and KATOIII cells, but not MKN-7, SKOV-3 or K562 cells (Fig. 3). These results indicated that the HER-2(905AA) peptide-induced CTLs recognized and lysed HER-2-expressing and HLA-A24(+) tumors.

CTL905AA clones recognize HLA-A24 tumor cell lines overexpressing HER-2 and TISI target cells pulsed with the HER-2(905) wild type peptide

To further analyze the specificity of the HER-2(905AA) peptide, CTL clones were generated by limiting dilution methods from the CTL905AA line. Using the HER-2(905AA)–HLA-A24 tetramer, CTL 905AA clone, clone M2 was stained positive for both CD8 and the 905AA tetramer (Fig. 4), indicating that the T cell clone M2 was HER-2(905AA)-specific. In addition, clone M2 recognized the TISI cells pulsed with HER-2(905AA) peptide and also, to a lesser extent, TISI pulsed with the HER-2(905) wild type peptide (Fig. 5). These results revealed that the MHC anchor-substituted analog epitope HER-2(905AA) was more effective at breaking tolerance and inducing CTL which recognized the HER-2(905) wild type peptide, than the HER-2(905) wild type peptide

Table 1 Relative binding affinity of HER-2/neu-derived peptides to HLA-A24

Peptide	Sequence	A24 binding[2] IC_{50}
Wild type peptide		
HER-2(8)	RWGLLLALL	11.41
HER-2(780)	PYVSRLLGI	77.14
HER-2(951)	VYMIMVKCW	79.93
HER-2(440)	AYSLTLQGL	97.98
HER-2(907)	SYGVTVWEL	101.42
HER-2(905)	VWSYGVTVW	173.21
HER-2(63)	TYLPTNASL	323.50
HER-2(968)	RFRELVSEF	744.21
HER-2(342)	CYGLGMEHL	780.14
HER-2(887)	KWMALESIL	887.79
Substitution analog		
HER-2(8AA)	RYGLLLALF	1.47
HER-2(780A)	PYVSRLLGF	9.23
HER-2(905AA)	VYSYGVTVF	17.89
HER-2(887AA)	KYMALESIF	19.97
HER-2(951A)	VYMIMVKCF	19.98
HER-2(907A)	SYGVTVWEF	27.82
HER-2(968A)	RYRELVSEF	37.21
HER-2(414AA)	AYPDSLPDF	42.97
HER-2(63A)	TYLPTNASF	46.02



Fig. 1 The specificities of the HER-2 peptide-inducing CTL lines were evaluated with Elispot assay. Sixteen HER-2-derived peptide-specific CTL lines, designated by the inducing peptide epitope, were generated from five different HLA-A24(+) healthy donors by using mature DC cells pulsed with each peptide. Then, the CTL lines were tested for their specificity against cognate peptides, which were used for each CTL induction, in an Elispot assay described in Material and methods. Elispot assays were performed against all the CTL lines generated from five different healthy donors. Representative data from five independent experiments are shown. In the present study, each peptide was considered positive if the spot forming cells (SFC) of the CTL line against TISI targets pulsed with cognate peptide is more than the twofold SFC of CTL only. As a result, CTL780A, CTL905AA and CTL414AA significantly recognized TISI targets pulsed with each cognate peptide. *Error bars* indicate the standard error of the mean



Fig. 2 Reactivities for the HER-2-expressing tumor by peptide-inducing CTL lines were evaluated with the Elispot assay. The CTL780A, CTL905AA and CTL414AA lines, which were generated from five different healthy donors, were tested against tumor cell lines in an Elispot analysis described in Material and methods. Representative data from five independent experiments are shown. In the present study, the response of the CTL line against the tumor cell line was positive if the SFC of the CTL line against a HLA-A24 positive HER-2 positive tumor cell line is more than threefold the SFC of a CTL line against a HLA-A24 negative HER-2 positive tumor cell line. Out of the three CTL lines, only the CTL 905AA line recognized HLA-A24 positive tumor cell lines overexpressing HER-2 (PC-9 and HCT-15), but not the HLA-A24 negative HER-2 positive MKN-7 tumor cell line. *Error bars* indicate the standard error of the mean



Fig. 3 Cytotoxic assay by CTL905AA line. CTL905AA lines generated from five different healthy donors were tested against several targets using 4 h ^{51}Cr-release assays at various effector/target ratios described in Material and methods. Representative data from five independent experiments are shown. CTL905AA line lysed HER-2(+), HLA-A24(+) HCT-15 and KATOIII, but not MKN-7, SKOV-3 or K562. HER-2 expression on the tumor cells was evaluated by flow cytometric analysis. Statistical analysis was performed with the Student's *t* test. $*P<0.05$. *MFI* mean fluorescence intensity

which was less effective at inducing a primary in vitro CTL response (Fig. 1).

To further confirm the reactivity of the HER-2(905AA) peptide, various doses of the HER-2(905AA) peptides were tested for their capacity for sensitizing TISI by the clone M2. As expected, the reactivity of HER-2(905AA) peptide was dose-dependent (Fig. 6).

Moreover, another CTL clone derived from the CTL905AA line, M5, also demonstrated cytotoxicity against HER-2(+), HLA-A24(+) targets (HCT-15, MRKnu-1, KATOIII and PC-9) specifically (Fig. 7). When cold target inhibition assays were performed, a significant (84.3 or 75.2% inhibition at the 1:10 hot to cold ratio) inhibition of the killing for the HCT-15 was observed only with non-radiolabeled TISI loaded with HER-2(905AA) peptide or HER-2(905) wild type peptide but not with TISI loaded with an irrelevant control HIV peptide (Fig. 8). Collectively, these data indicated the HER-2(905AA) MHC anchor-substituted analog can efficiently induce HER-2-specific, HLA-A24 restricted CTLs.

Discussion

In the present study, we have screened seven wild type peptides and nine HLA anchor-substituted analogs derived from HLA-A24 binding, HER-2-derived peptides as possible CTL epitopes. Then, we showed that the analog HER-2(905AA) can efficiently induce HER-2-



Fig. 4 Tetramer assay for the CTL905AA clone M2. HER-2(905AA)-reactive CTL clones were generated by limiting dilution methods from the CTL905AA line. HER-2(905AA) tetramer analysis showed that CTL905AA clone M2 was stained positive for both CD8 and the HLA-A24-HER-2(905AA) tetramer (93.4%)



Fig. 5 The reactivity of the CTL905AA clone M2 in Elispot analysis. The CTL905AA clone M2 recognized TISI pulsed with HER-2(905AA) peptide and also, to a lesser extent, TISI pulsed with the HER-2(905) wild type peptide

specific, HLA-A24 restricted CTLs, which recognize and lyse tumor cells presenting the naturally processed wild type HER-2 epitope.

Deliberate substitutions of amino acids in peptide epitopes are generally thought to be effective in inducing peptide-specific CTLs by improving the binding affinity to HLA molecules. In previous studies, analogs substituted at MHC anchor residues have been tested in several tumor Ags, such as GP2, NY-ESO-1, gp100 as well as MART-1, and some of them successfully improved the immunogenicity of the CTL epitopes [3, 15, 25, 32, 35]. In the present study, to improve the immunogenicity of relatively low binding, HER-2-derived peptides, we generated anchor-substituted analogs (Table 1) and tested them for the immunogenicity. Although every substituted analog resulted in the enhancement of the binding affinity to HLA-A24 molecules, only analogs HER-2(780A), HER-2(905AA) and HER-2(414AA) were effective in inducing a peptide-specific CTL response (Fig. 1). Furthermore, out of three analogs, only the HER-2(905AA)-specific CTL resulted in the recognition and lysis of HLA-A24 tumor cell lines overexpressing HER-2 and the EBV-transformed cell line TISI pulsed with its wild type peptide. In addition, the cold target inhibition assay using the HER-2(905AA)-specific CTL clone further supported that a newly identified HER-2(905) peptide epitope is presented as the CTL epitope on HER-2 overexpressing tumor cell lines (Fig. 8).



Fig. 6 Dose-dependent reactivity of the CTL905AA clone M2. To further confirm the reactivity of the CTL905AA clone M2, various doses of HER-2(905AA) peptide were tested for their capacity for sensitizing TISI by the CTL905AA clone M2 in an Elispot analysis. The reactivity of clone M2 for HER-2(905AA) peptide was dose-dependent. *Error bars* indicate the standard error of the mean

Fig. 7 The specificity of the CTL905AA clone M5 was evaluated with cytotoxic assay. The CTL905AA clone M5 was tested against several tumor cell lines using 4 h ^{51}Cr-release assays at various effector/target ratios. The clone M5 lysed the HER-2(+) and HLA-A24(+) tumor cell lines HCT-15, MRKnu-1, KATOIII and PC-9, while M5 did not react with WiDr, SKOV-3, MKN-7, K562 or TISI cells. HER-2 expression on the tumor cells was evaluated by the flow cytometric analysis. *MFI* mean fluorescence intensity



In general, low binding affinity for the MHC class I molecule makes it difficult to induce peptide-specific CTL as epitope peptides that have low binding affinity may permit T cells to escape from negative selection; however, these epitope peptides and T cells may be useful for tumor-specific immunity. In the present study, the HER-2(905AA) analog peptide, but not the HER-2(905) wild type peptide, was effective in inducing a peptide-specific CTL response, and the HER-2(905AA)-specific CTL specifically lysed TISI target cells pulsed with HER-2(905AA) compared to TISI targets pulsed with HER-2(905). It is possible that increased immunogenicity with the HER-2(905AA) peptide analog may be derived from a combination of efficient binding to HLA-A24 molecules and better interaction with T cell receptors of specific CTLs. It has been shown that MHC anchor-substituted analogs derived from gp100 or NY-ESO-1 can induce CTL responses more efficiently than their corresponding wild type peptide epitopes [3, 25].

Recently, we and a few others have suggested that tumor-specific immunotherapy based on HER-2-derived peptides may be a useful and novel approach to the treatment of cancer patients with HER-2 overexpressing tumors. In fact, we have shown that DCs pulsed with HER-2-derived, HLA-A2 restricted peptides can induce specific T cell responses in patients with gastric cancer [20]. HLA-A24 is one of the most common alleles in Japanese people and is shared by more than 60% of the Japanese gastric cancer patients [7]. Thus, it would be desirable to identify additional HLA-A24 restricted immunodominant epitope peptides derived from HER-2, in order to broaden tumor-specific immunotherapy based on HER-2. The HER-2(905AA) peptide analog could be used as cancer vaccine to induce potent anti-tumor CTL responses. We believe that HER-2-specific, HLA-A24 restricted CTLs generated by HER-2(905AA) may react with HER-2 overexpressing tumor in vivo. In conclusion, the substitution analog peptide, HER-2(905AA), can efficiently induce HER-2-specific, HLA-A24 restricted CTLs.



Fig. 8 Cold target inhibition assays with the CTL905AA clone M5. Cold target inhibition assays were performed using non-radiolabeled TISI cells loaded with the HER-2(905AA) peptide, the HER-2(905) wild type peptide or an irrelevant HIV peptide at various hot/cold target ratios. A significant (84.3 or 75.2% inhibition at the 1:10 hot to cold ratio) inhibition of the killing for the HER-2(+) and HLA-A24(+) HCT-15 mediated by clone M5 was observed when non-radiolabeled TISI cells loaded with HER-2(905AA) peptide or HER-2(905) peptide were added, but not when TISI cells were loaded with the control HIV peptide. *E:T* effector:hot target ratio

Acknowledgments This work was supported by a grant from the Ministry of Education, Culture, Sports, Science and Technology in Japan.

References

1. Brichard V, Van Pel A, Wolfel T, Wolfel C, De Plaen E, Lethe B, Coulie P, Boon T (1993) The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 178:489–495
2. Celis E, Tsai V, Crimi C, DeMars R, Wentworth PA, Chesnut RW, Grey HM, Sette A, Serra HM (1994) Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes. Proc Natl Acad Sci USA 91:2105–2109
3. Chen JL, Dunbar PR, Gileadi U, Jager E, Gnjatic S, Nagata Y, Stockert E, Panicali DL, Chen YT, Knuth A, Old LJ, Cerundolo V (2000) Identification of NY-ESO-1 peptide analogues capable of improved stimulation of tumor-reactive CTL. J Immunol 165:948–955
4. Coulie PG, Brichard V, Van Pel A, Wolfel T, Schneider J, Traversari C, Mattei S, De Plaen E, Lurquin C, Szikora JP, Renauld JC, Boon T (1994) A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 180:35–42
5. Coussens L, Yang-Feng TL, Liao YC, Chen E, Gray A, McGrath J, Seeburg PH, Libermann TA, Schlessinger J, Francke U et al (1985) Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 230:1132–1139
6. Cox AL, Skipper J, Chen Y, Henderson RA, Darrow TL, Shabanowitz J, Engelhard VH, Hunt DF, Slingluff CL Jr (1994) Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science 264:716–719
7. Date Y, Kimura A, Kato H, Sasazuki T (1996) DNA typing of the HLA-A gene: population study and identification of four new alleles in Japanese. Tissue Antigens 47:93–101
8. Fisk B, Blevins TL, Wharton JT, Ioannides CG (1995) Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. J Exp Med 181:2109–2117
9. Ikuta Y, Okugawa T, Furugen R, Nagata Y, Takahashi Y, Wang L, Ikeda H, Watanabe M, Imai S, Shiku H (2000) A HER2/NEU-derived peptide, a K(d)-restricted murine tumor rejection antigen, induces HER2-specific HLA-A2402-restricted CD8(+) cytotoxic T lymphocytes. Int J Cancer 87:553–558
10. Ishikawa T, Kobayashi M, Mai M, Suzuki T, Ooi A (1997) Amplification of the c-erbB-2 (HER-2/neu) gene in gastric cancer cells. Detection by fluorescence in situ hybridization. Am J Pathol 151:761–768
11. Kawakami Y, Eliyahu S, Delgado CH, Robbins PF, Sakaguchi K, Appella E, Yannelli JR, Adema GJ, Miki T, Rosenberg SA (1994) Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci USA 91:6458–6462
12. Kawakami Y, Eliyahu S, Sakaguchi K, Robbins PF, Rivoltini L, Yannelli JR, Appella E, Rosenberg SA (1994) Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J Exp Med 180:347–352
13. Kawakami Y, Eliyahu S, Jennings C, Sakaguchi K, Kang X, Southwood S, Robbins PF, Sette A, Appella E, Rosenberg SA (1995) Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J Immunol 154:3961–3968
14. Kawashima I, Hudson SJ, Tsai V, Southwood S, Takesako K, Appella E, Sette A, Celis E (1998) The multi-epitope approach for immunotherapy for cancer: identification of several CTL epitopes from various tumor-associated antigens expressed on solid epithelial tumors. Hum Immunol 59:1–14
15. Keogh E, Fikes J, Southwood S, Celis E, Chesnut R, Sette A (2001) Identification of new epitopes from four different tumor-associated antigens: recognition of naturally processed epitopes correlates with HLA-A*0201-binding affinity. J Immunol 167:787–796
16. Kondo A, Sidney J, Southwood S, del Guercio MF, Appella E, Sakamoto H, Celis E, Grey HM, Chesnut RW, Kubo RT, Sette A (1995) Prominent roles of secondary anchor residues in peptide binding to HLA-A24 human class I molecules. J Immunol 155:4307–4312
17. Kono K, Halapi E, Hising C, Petersson M, Gerdin E, Vanky F, Kiessling R (1997) Mechanisms of escape from CD8+ T-cell clones specific for the HER-2/neu proto-oncogene expressed in ovarian carcinomas: related and unrelated to decreased MHC class 1 expression. Int J Cancer 70:112–119
18. Kono K, Rongcun Y, Charo J, Ichihara F, Celis E, Sette A, Appella E, Sekikawa T, Matsumoto Y, Kiessling R (1998) Identification of HER2/neu-derived peptide epitopes recognized by gastric cancer-specific cytotoxic T lymphocytes. Int J Cancer 78:202–208
19. Kono K, Takahashi A, Amemiya H, Ichihara F, Sugai H, Iizuka H, Fujii H, Matsumoto Y (2002) Frequencies of HER-2/neu overexpression relating to HLA haplotype in patients with gastric cancer. Int J Cancer 98:216–220
20. Kono K, Takahashi A, Sugai H, Fujii H, Choudhury AR, Kiessling R, Matsumoto Y (2002) Dendritic cells pulsed with HER-2/neu-derived peptides can induce specific T-cell responses in patients with gastric cancer. Clin Cancer Res 8:3394–3400
21. Kubo RT, Sette A, Grey HM, Appella E, Sakaguchi K, Zhu NZ, Arnott D, Sherman N, Shabanowitz J, Michel H et al (1994) Definition of specific peptide motifs for four major HLA-A alleles. J Immunol 152:3913–3924
22. Linehan DC, Goedegebuure PS, Peoples GE, Rogers SO, Eberlein TJ (1995) Tumor-specific and HLA-A2-restricted cytolysis by tumor-associated lymphocytes in human metastatic breast cancer. J Immunol 155:4486–4491
23. Mayordomo JI, Zorina T, Storkus WJ, Zitvogel L, Celluzzi C, Falo LD, Melief CJ, Ildstad ST, Kast WM, Deleo AB et al (1995) Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat Med 1:1297–1302
24. Okugawa T, Ikuta Y, Takahashi Y, Obata H, Tanida K, Watanabe M, Imai S, Furugen R, Nagata Y, Toyoda N, Shiku H (2000) A novel human HER2-derived peptide homologous to the mouse K(d)-restricted tumor rejection antigen can induce HLA-A24-restricted cytotoxic T lymphocytes in ovarian cancer patients and healthy individuals. Eur J Immunol 30:3338–3346
25. Parkhurst MR, Salgaller ML, Southwood S, Robbins PF, Sette A, Rosenberg SA, Kawakami Y (1996) Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues. J Immunol 157:2539–2548
26. Rongcun Y, Salazar-Onfray F, Charo J, Malmberg KJ, Evrin K, Maes H, Kono K, Hising C, Petersson M, Larsson O, Lan L, Appella E, Sette A, Celis E, Kiessling R (1999) Identification of new HER2/neu-derived peptide epitopes that can elicit specific CTL against autologous and allogeneic carcinomas and melanomas. J Immunol 163:1037–1044
27. Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Topalian SL, Toy ST, Simon P, Lotze MT, Yang JC, Seipp CA et al (1988) Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med 319:1676–1680
28. Ruppert J, Sidney J, Celis E, Kubo RT, Grey HM, Sette A (1993) Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules. Cell 74:929–937
29. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A et al (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707–712

30. Takehana T, Kunitomo K, Kono K, Kitahara F, Iizuka H, Matsumoto Y, Fujino MA, Ooi A (2002) Status of c-erbB-2 in gastric adenocarcinoma: a comparative study of immunohistochemistry, fluorescence in situ hybridization and enzyme-linked immuno-sorbent assay. Int J Cancer 98:833–837
31. Tanaka H, Tsunoda T, Nukaya I, Sette A, Matsuda K, Umano Y, Yamaue H, Takesako K, Tanimura H (2001) Mapping the HLA-A24-restricted T-cell epitope peptide from a tumour-associated antigen HER2/neu: possible immunotherapy for colorectal carcinomas. Br J Cancer 84:94–99
32. Tanaka Y, Amos KD, Joo HG, Eberlein TJ, Goedegebuure PS (2001) Modification of the HER2/NEU-derived tumor antigen GP2 improves induction of GP2-reactive cytotoxic T lymphocytes. Int J Cancer 94:540–544
33. Traversari C, van der Bruggen P, Luescher IF, Lurquin C, Chomez P, Van Pel A, De Plaen E, Amar-Costesec A, Boon T (1992) A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. J Exp Med 176:1453–1457
34. Tsai V, Southwood S, Sidney J, Sakaguchi K, Kawakami Y, Appella E, Sette A, Celis E (1997) Identification of subdominant CTL epitopes of the GP100 melanoma-associated tumor antigen by primary in vitro immunization with peptide-pulsed dendritic cells. J Immunol 158:1796–1802
35. Valmori D, Fonteneau JF, Lizana CM, Gervois N, Lienard D, Rimoldi D, Jongeneel V, Jotereau F, Cerottini JC, Romero P (1998) Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues. J Immunol 160:1750–1758

Cancer Immunol Immunother (2005)
DOI 10.1007/s00262-005-0092-8

ORIGINAL ARTICLE

Koji Kono · Hiromichi Kawaida · Akihiro Takahashi
Hidemitsu Sugai · Kosaku Mimura · Naoto Miyagawa
Hideo Omata · Hideki Fujii

CD4(+)CD25^{high} regulatory T cells increase with tumor stage in patients with gastric and esophageal cancers

Received: 30 May 2005 / Accepted: 13 October 2005
© Springer-Verlag 2005

Abstract *Purpose*: Regulatory T cells (T regs) can inhibit immune responses mediated by T cells. It has been shown that there is an increased proportion of T regs in several different human malignancies, although the actual mechanism remains unclear. In the present study, we evaluated the prevalence of CD4(+)CD25^{high} T regs in PBMCs from patients with gastric and esophageal cancers in relation to the clinical outcome. *Methods*: PBMCs in 72 patients with gastric cancer and 42 patients with esophageal cancer were evaluated for the proportion of CD4(+)CD25^{high} T cells, as a percentage of the total CD4(+) cells, by flow cytometric analysis with triple-color staining. Actuarial overall survival rates of the patients were analyzed by the Kaplan–Meier method. *Results*: The percentages of CD4(+)CD25^{high} T cells for cases of gastric cancer ($4.9\pm1.2\%$) and esophageal cancer ($5.2\pm2.1\%$) were significantly higher than those for healthy donors ($1.9\pm1.1\%$, $P<0.01$). There were significant differences in the prevalence of CD4(+)CD25^{high} T cells between the early and advanced disease stages, both in gastric cancer (stage I vs. III, $P<0.05$; stage I vs. IV, $P<0.05$) and esophageal cancer (stage I vs. IV, $P<0.05$). The patients with a high proportion of CD4(+)CD25^{high} T cells showed poorer survival rates in comparison to those with a low proportion, in both gastric and esophageal cancers. After patients received curative resections of gastric cancers ($n=57$), the increased proportions of CD4(+)CD25^{high} T cells were significantly reduced, and the levels were almost equal to those in normal healthy donors. In addition, studies of gastric cancer patients with postoperative recurrent tumors ($n=6$) revealed that the prevalence of CD4(+)CD25^{high} T cells individually increased compared to 2 months after the operations. CD4(+)CD25^{high} T cells expressed FOXP3 mRNA and had abundant CD45RO and intracellular CTLA-4 molecules. *Conclusions*: These results strongly suggest that tumor-related factors induce and expand CD4(+)CD25^{high} T regs.

Keywords Regulatory T cells · Gastric cancer · Esophageal cancer · CD4(+)CD25^{high} T cells

K. Kono (✉) · H. Kawaida · A. Takahashi · H. Sugai
K. Mimura · N. Miyagawa · H. Omata · H. Fujii
First Department of Surgery, University of Yamanashi,
1110 Shimokato, Tamaho, 409-3898 Yamanashi, Japan
E-mail: kojikono@yamanashi.ac.jp
Tel.: +81-55-2737390
Fax: +81-55-2739574

Introduction

Regulatory T cells (T regs) are thought to be a functionally unique population of T cells, and function to maintain immune homeostasis [1–4]. T regs can inhibit immune responses mediated by CD4(+) and CD8(+) T cells, and it was reported that T regs play an important role in preventing allograft rejection, graft-versus-host disease, and autoimmune disease [5, 6].

Within CD4(+) T cells with a suppressive function, there are at least three different cell populations: CD25(+)CD4(+)-naturally occurring T regs, IL-10-producing Tr1 cells, and Th3 cells [7–14]. Furthermore, although CD25(+)CD4(+)-naturally occurring T regs were originally characterized by the coexpression of CD4 and CD25 in mice, it has recently been shown in humans that the CD4(+)CD25^{high} subset corresponded to naturally occurring T regs populations with a suppressive capacity, while CD4(+)CD25^{int} T cells contaminated effector or memory T cells with no suppressive capacity [15–17].

There is accumulating evidence that increased populations of T regs are present in patients with gastric cancer [18–20], colorectal cancer, gall bladder cancer, pancreatic cancer [20, 21], ovarian cancer [22], and lung cancer [23]. Moreover, we showed that the population of T regs in tumor-infiltrating lymphocytes (TILs) of patients with advanced gastric cancer was significantly larger than that of TILs in patients with early gastric cancer [18].

There is no clear evidence to suggest the mechanisms for the induction of T regs in cancer-bearing hosts. It has recently been shown that tumor cells and microenvironmental macrophages produce the chemokine CCL20, which mediates the trafficking of T regs to the tumor [24]. Also, we have shown that the levels of CD4(+)CD25^{high} T regs in tumor-draining lymph nodes adjacent to tumors were greater than those distant from tumors [25]. These data indicate that tumor-derived factors may induce and expand T regs pools.

In the present study, we evaluated the prevalence of CD4(+)CD25^{high} T regs in PBMCs from patients with gastric and esophageal cancers, and clarified the correlation between prevalence and clinical outcome for the patients.

Materials and methods

Patients

Seventy-two patients with gastric cancer and 42 patients with esophageal cancer, who were treated in the University of Yamanashi Hospital from 1999 to 2000, were enrolled in the present study, and their clinical features were evaluated according to the TNM classification for gastric and esophageal cancers. The patients with gastric cancer were 70.8 ± 18.3 years old (mean ± SD), and 40 patients were men and 32 were women. Thirty-six tumors belonged to stage I, 8 were stage II, 8 were stage III, and 20 tumors were stage IV.

The patients with esophageal cancer were 72.9 ± 11.3 years old, and 40 patients were men and 2 were women. Three tumors belonged to stage I, 16 were stage II, 15 were stage III, and 8 tumors were stage IV.

None of the patients received radiotherapy, chemotherapy, or other medical interventions before the study. This study was approved by the ethical committee of the University of Yamanashi, and written informed consent was obtained from all individuals.



Fig. 2 Increased populations of CD4(+)CD25^{high} T cells in PBMCs from patients with gastric and esophageal cancers. The percentages of CD4(+)CD25^{high} T cells in cases of gastric ($n = 72$, 4.9 ± 1.2%) and esophageal cancers ($n = 42$, 5.2 ± 2.1%) were significantly higher than those of healthy donors ($n = 16$, 1.9 ± 1.1%, $P < 0.01$). There were significant differences in the prevalence of CD4(+)CD25^{high} T cells between stage I and III ($P < 0.05$), stage I and IV ($P < 0.05$) in gastric cancer, as well as stage I and IV ($P < 0.05$) in esophageal cancer. Stage classification was defined according to the TNM classification

Cell preparations

PBMCs were isolated with a Ficoll (Amersham, Uppsala, Sweden) density gradient and routinely stored in liquid nitrogen in Cell Stock Media (IBL, Gumma, Japan).

Flow cytometric analysis

PBMCs were stained for molecules to determine their immunophenotype using anti-CD25-FITC, anti-CD4-PerCP, anti-CD3-APC, anti-CD152 (CTLA4)-PE, and



Fig. 1 CD4(+)CD25^{high} T cells in PBMCs from patients with gastric and esophageal cancers. The population of CD4(+)CD25^{high} T cells as a percentage of the total CD4(+) cells was evaluated by flow cytometric analysis with triple-color staining. Representative flow cytometric data from gastric (stage III) and esophageal cancer patients (stage III) and healthy donors are shown. *Rectangular gates* indicate CD4(+)CD25^{high} T cell populations



Fig. 3 The expression of CD45RO and intracellular CTLA-4(CD152) on CD4(+)CD25^{high} T cells. Representative flow cytometric data from gastric cancer patients (stage III) showed the expression of CD45RO and intracellular CTLA-4 after the gating of CD4(+)CD25^{high} T cells

anti-CD45RO-PE (Dako, Glosprup, Denmark) antibodies. Triple- or four-color flow cytometry was performed using FACSCalibur (Becton Dickinson, San Jose, CA, USA). Cells were analyzed using Cell Quest software.

To analyze the prevalence of T regs, CD4(+) CD25^{high} cells after gating on CD3(+) were evaluated and expressed as a percentage of the total CD4(+) cells.

Intracellular cytokine assay

Briefly, cells were incubated in RPMI 1640 (Sigma-Aldrich Cheme, Taufkirchen, Germany) with 5% FCS, 2 μl IC block (Biosource, Camarillo, CA, USA), and 2 μl phorbol myristate acetate (PMA, Sigma-Aldrich Cheme; final concentration of 25 ng/μl) for 4 h at 37°C. After staining with anti-CD25-FITC and anti-CD4-PerCP (Dako) for 30 min on ice and subsequent washing, cells were fixed in IC-Fix (Biosource) for 10 min on ice and washed twice with IC perm (Biosource). Thereafter, cells were stained with either the IgG negative control (Biosource), rat anti-human IL-10-PE (Biosource) or rat anti-human IFN-γ-PE (Biosource) and washed twice.

FOXP3 RT-PCR analysis

CD4(+)CD25^{high} T regs were separated by FACS sorting from PBMCs in gastric cancer patients ($n=6$). Total RNA was extracted from sorted CD4(+)CD25^{high} T cells according to the standard protocol with an RNeasy Minikit (Qiagen K.K., Tokyo, Japan). One microgram of total RNA was added to the reaction mixture using the OneStep RT-PCR Kit (Qiagen) and amplified in a GeneAmp PCR System 9700 (Applied Biosystems, CA, USA). Specific primers were designed as follows: *FOXP3* primers, CAG CTG CCC ACA CTG CCC CTA G (forward) and CAT TTG CCA GCA GTG GGT AG (reverse); *β-actin* primers, CTA CAA TGA GCT GCG TGT GC (forward) and CGG TGA GGA TCT TCA TGA GG (reverse). After the RT reaction with one cycle of 30 min at 50°C and 15 min at 95°C, for *FOXP3* PCR, the cycling conditions were as follows: 35 cycles of 45 s at 94°C for denaturation, 45 s at 59°C for annealing, and 1 min at 72°C for elongation. The amplified product (382 bp for *FOXP3* and 314 bp for *β-actin*) was electrophoresed on a 1.2% agarose gel (Ultra Pure, GIBCO BRL, New York, NY, USA) and equilibrated in TAE (40 mM Tris–acetate, 2 mM EDTA). Ethidium bromide (0.5 μg/ml) was added to the agarose–TAE gels with TAE electrophoresis buffers to visualize the amplified DNA fragments, and these were photographed using Polaroid film 667 under UV light.

Statistical analysis

Differences between the values were determined using the nonpaired or paired Student's *t* test. Actuarial overall survival rates were analyzed by the Kaplan–Meier method and survival was measured in days from diagnosis to death or the last review. The log-rank test was applied to compare the two groups. Multivariate analysis of prognostic factors for overall survival was made using Cox's proportional hazards model. All statistical analyses were performed using Statview 5.0 for Windows software and a significant difference was considered as $P<0.05$.

Results

Increased populations of CD4(+)CD25^{high} T cells in patients with gastric and esophageal cancers

PBMCs in patients with gastric cancer ($n=72$), esophageal cancer ($n=42$), and in healthy donors ($n=16$) were examined for the prevalence of CD4(+)CD25^{high} T cells as T regs, and the population of CD4(+)CD25^{high} T cells as a percentage of the total CD4(+) cells was evaluated. In representative flow cytometric data, the prevalence of CD4(+)CD25^{high} T cells in patients with gastric and esophageal cancers was higher than that in healthy donors (Fig. 1). Summarized data from all

Fig. 4 Intracellular cytokine staining of CD4(+)CD25^{high} T cells. Intracellular cytokine staining (IFN-γ and IL-10) was performed gated on CD4(+)CD25^{high} T cells (**a**) or CD4(+)CD25^{int} T cells (**b**) derived from the PBMCs in the gastric cancer patient (stage III)



individuals indicated that the percentages of CD4(+)CD25^{high} T cells in gastric cancer patients (4.9±1.2%) and esophageal cancer patients (5.2±2.1%) were significantly higher than those of healthy donors (1.9±1.1%, $P<0.01$), as shown in Fig. 2. Moreover, there were significant differences in the prevalence of CD4(+)CD25^{high} T cells between the early and advanced disease stages, both in gastric cancer (stage I vs. III, $P<0.05$; stage I vs. IV, $P<0.05$) and esophageal cancer (stage I vs. IV, $P<0.05$). These observations indicated that a tumor-bearing host with an advanced disease stage had an increased prevalence of CD4(+)CD25^{high} T cells in PBMCs in comparison to those with early disease stages or healthy donors.

Characterization of CD4(+)CD25^{high} T cells

In order to characterize the CD4(+)CD25^{high} T cells tested, we analyzed markers such as CD45RO and

Table 1 Significance of prognostic factors in multivariate survival analysis for patients with gastric and esophageal cancers

	Gastric cancer			Esophageal cancer		
	Hazard ratio	95% CI	*P* value	Hazard ratio	95% CI	*P* value
CD4(+)CD25^{high} T cells						
High	1.0	–	–	1.0	–	–
Low	0.81	0.93–4.57	0.71	0.72	0.30–1.41	0.56
Primary tumor[a]						
PTis–pT1b	1.0	–	–	1.0	–	–
PT2	2.85	0.92–5.18	0.74	4.21	1.06–19.52	0.04
PT3	2.28	0.61–11.55	0.63	2.93	0.66–13.95	0.11
Lymph node metastasis						
Negative	1.0	–	–	1.0	–	–
Positive	1.19	0.62–1.87	0.80	1.95	0.40–9.08	0.33
Stage[a]						
0–2	1.0	–	–	1.0	–	–
3–4	2.01	0.91–3.05	0.09	2.91	0.50–12.53	0.75

[a]The grade of tumor and stages were defined according to the UICC (TMN) classification

intracellular CTLA-4 (CD152). The expressions of CTLA-4 and CD45RO were analyzed in the gated CD4(+)CD25^{high} T cells. Representative flow cytometric data from gastric cancer patients with advanced disease stages showed that most of the CD4(+)CD25^{high} T cells expressed CD45RO and intracellular CTLA-4 (Fig. 3).

Furthermore, representative flow cytometric data with intracellular cytokine staining showed that CD4(+)CD25^{high} T cells derived from gastric cancer patients with advanced disease stages produced small amounts of IL-10 (Fig. 4a). In contrast, CD4(+)CD25^{int} T cells produced large amounts of IL-10 (Fig. 4b). Furthermore, CD4(+)CD25^{high} T cells as well as CD4(+)CD25^{int} T cells did not produce significant amount of IFN-γ (Fig. 4a, b), in line with previous reports [15–18, 25]. Thus, CD4(+)CD25^{high} T cells separated from PBMCs in the patients corresponded to CD25(+)CD4(+)-naturally occurring T regs [15–17].



Fig. 5 FOXP3 mRNA analysis of CD4(+)CD25^{high} T cells. CD4(+)CD25^{high} T regs were separated by FACS sorting on CD4(+)CD25^{high} T cells in PBMCs from gastric cancer patients (stage III and IV). Total RNA was extracted from sorted CD4(+)CD25^{high} T cells (*samples 1–4*) or CD4(+)CD25int T cells (*samples 5, 6*) and RT-PCR analyze specific for FOXP3 mRNA was performed

FOXP3 analysis of CD4(+)CD25^{high} T cells

CD4(+)CD25^{high} T regs were separated by FACS sorting from the PBMCs of gastric cancer patients ($n=6$). Total RNA was extracted from sorted CD4(+)CD25^{high} T cells and RT-PCR analyze specific for *FOXP3 mRNA* was performed. Representative RT-PCR analysis is shown in Fig. 5 and sorted CD4(+)CD25^{high} T cells showed FOXP3 specific bands, indicating that CD4(+)CD25^{high} T cells corresponded to CD25(+)CD4(+)-naturally occurring T regs [15].

Survival rates of patients in relation to the prevalence of CD4(+)CD25^{high} T cells

When the patients were separated into high or low prevalence of T regs groups, classified by the mean values of CD4(+)CD25^{high} T cells (4.9% for gastric cancer and 5.2% for esophageal cancer), the gastric cancer patients with high numbers of CD4(+)CD25^{high} T cells (stage I, $n=5$; stage II, $n=6$; stage III, $n=7$; stage IV, $n=20$) showed significantly poorer survival rates in comparison to those with low numbers of CD4(+)CD25^{high} T cells (stage I, $n=31$; stage II, $n=2$; stage III, $n=1$) (Fig. 6a). Similarly, esophageal cancer patients with high numbers of CD4(+)CD25^{high} T cells (stage I, $n=1$; stage II, $n=2$; stage III, $n=11$; stage IV, $n=8$) showed significantly poorer survival rates in comparison to those with low numbers of CD4(+)CD25^{high} T cells (stage I, $n=2$; stage II, $n=14$; stage III, $n=4$) (Fig. 6b).

To assess whether prevalence of CD4(+)CD25^{high} T cells represented a prognostic parameter, we used Cox's proportional hazards model. The covariate parameters included stage of the disease, depth of tumor invasion, lymph-node metastasis, and prevalence of CD4(+) CD25^{high} T cells. Multivariate analysis revealed that the



Fig. 6 Survival rates of patients in relation to the prevalence of CD4(+)CD25^{high} T cells. PBMCs were separated prior to the operation and analyzed for the prevalence of CD4(+)CD25^{high} T cells. When the patients were separated into high or low prevalence of T regs groups, classified by the mean values of CD4(+)CD25^{high} T cells, gastric cancer patients with high CD4(+)CD25^{high} T cell levels ($n = 38$) showed poorer survival rates in comparison to those with low CD4(+)CD25^{high} T cell levels ($n = 34$), analyzed by the log-rank test (**a**). Similarly, esophageal cancer patients with high CD4(+)CD25^{high} T cell levels ($n = 22$) showed poorer survival rates in comparison to those with low CD4(+)CD25^{high} T cell levels ($n = 20$) (**b**)

prevalence of CD4(+)CD25^{high} T cells was not an independent prognostic factor (Table 1).

Clinical significance of the prevalence of CD4(+)CD25^{high} T cells

In order to clarify the levels of CD4(+)CD25^{high} T cells in PBMCs from patients with or without tumor-bearing status, we compared preoperative and postoperative (2 months after the operation) levels. After patients received curative resections of gastric cancers ($n = 57$), the increased proportions of CD4(+)CD25^{high} T cells were significantly reduced, and the levels were almost equal to those in healthy donors (Fig. 7a). In addition, studies of gastric cancer patients with postoperative recurrent tumors ($n = 6$) revealed that the prevalence of CD4(+)CD25^{high} T cells individually increased compared to the periods without tumors (Fig. 7b). These results strongly suggest that tumor-related factors induce and expand T regs.

Discussion

The current report provides evidence for the relationship between the prevalence of CD4(+)CD25^{high} T regs in PBMCs and the clinical outcome in patients with gastric and esophageal cancers. We showed that patients with high levels of CD4(+)CD25^{high} T cells showed more advanced stages and poorer survival rates in comparison to those with low CD4(+)CD25^{high} T cell levels. Furthermore, after patients had received curative resections of tumors, the increased levels of CD4(+)CD25^{high} T cells significantly decreased to the levels of healthy donors.

Increased proportions of CD4(+)CD25(+) T cells in PBLs and TILs have been reported in several different human malignancies [18–23]. We recently reported about increased populations of CD4(+)CD25(+) T cells in PBL and TILs [18], and elevated CD4(+)CD25^{high} T cell levels in the tumor-draining lymph nodes [25] of patients with gastric cancer. In the

present study, we confirmed the increased prevalence of CD4(+)CD25^{high} T cells in PBMCs in larger cohorts in cases of gastric and esophageal cancers. Furthermore, we showed that patients with high levels of CD4(+) CD25^{high} T cells revealed poorer survival rates in comparison to those with low CD4(+)CD25^{high} T cell levels, in line with previous reports [20, 24]. However, multivariate analysis in the present study revealed that the prevalence of CD4(+)CD25^{high} T cells was not an independent prognostic factor. Since the sample size of the present study was limited and the groups were not sufficiently matched in composition, further studies will be needed to draw valid conclusion for the prognostic factor.



Fig. 7 Clinical course of patients in relation to the prevalence of CD4(+)CD25^{high} T cells. The prevalence of CD4(+)CD25^{high} T cells between preoperative and postoperative (2 months after the operation) periods are shown in **a**. After patients had received curative resections of gastric cancers ($n = 57$), the increased levels of CD4(+)CD25^{high} T cells were significantly reduced, analyzed by the paired t test (a). In addition, studies for gastric cancer patients with postoperative recurrent tumors ($n = 6$, postrecurrence) showed that the prevalence of CD4(+)CD25^{high} T cells individually increased in comparison to 2 months after the operation (prerecurrence) (**b**)

It has recently been shown that human CD4(+) CD25(+) T cells are not homogenous, and can be split into suppressive and nonsuppressive fractions by sorting CD25^{high} and CD25^{int} cells [15]. Furthermore, it was proposed that only a subset of high levels of CD25 and CTLA-4 molecules within CD4(+)CD25(+) T cell populations was capable of inducing a suppressive function, and that there was a difference in cytokine production profiles between CD25^{high} and CD25^{int} cells within CD4(+)CD25(+) T cells [15–17, 26, 27]. In the present study, we focused on CD4(+)CD25^{high} T cells as CD25(+)CD4(+)-naturally occurring T regs and evaluated the prevalence of CD4(+)CD25^{high} T cells in PBMCs. These subsets showed strong expressions of intracellular CTLA-4 and CD45RO and small amounts of IL-10 production, as indicated in a previous report which suggested that CD4(+)CD25^{high} T cells may correspond to human naturally occurring T regs [15]. In addition, we confirmed *FOXP3 mRNA* expression on CD4(+)CD25^{high} T cells in the present study. These results indicate that the population of CD4(+)CD25^{high} T cells in the present study correspond to human naturally occurring T regs. Since there is still a debate regarding the marker of T regs [15], further studies are required at a cloned T cell level or at a molecular level which targets more specific markers or functional profiles.

There is no clear evidence to suggest the mechanisms for the induction of T regs in cancer-bearing hosts. However, there are several possibilities, including the specific expansion of T regs induced by cancer-derived factors, or physiological defense phenomena against continuous inflammation induced by cancer. It has recently been shown that tumor cells and microenvironmental macrophages produce the chemokine CCL20, which mediates the trafficking of T regs to the tumor [24]. Also, we have shown that the levels of CD4(+)CD25^{high} T regs in tumor-draining lymph nodes adjacent to tumors were greater than those distant from tumors [25]. Furthermore, in the present study, we reported that after patients had received curative resections of tumors, the increased levels of CD4(+)CD25^{high} T cells were significantly reduced, and that the levels recovered to those of healthy donors. These results strongly suggest that tumor-derived factors may induce and expand T regs pools, although the precise mechanisms regulating CD4(+)CD25^{high} T regs remain unknown.

Recently, immunotherapy for cancer, including cancer vaccination or adoptive transfer of T cells, has been tested, but the results suggested it was limited in the effect on the regression of established tumors [28, 29]. The increased population of T regs, especially in the tumor environment, is one of the problems to be resolved in cancer immunotherapy. It was shown that the efficacy of therapeutic vaccination for cancer could be enhanced by removing T regs [30]. A better understanding of the underlying mechanism of T regs

regulation or a strategy for controlling T regs may lead to more effective immunotherapies against cancer.

Acknowledgment This work was supported by a grant from the Ministry of Education, Culture, Sports, Science and Technology in Japan.

References

1. Joneleit H, Schmitt E, Stassen M, Tuettenberg A, Knop J, Enk AH (2001) Identification and functional characterization of human CD4(+)CD25(+) T cells with regulatory properties isolated from peripheral blood. J Exp Med 193:1285–1294
2. Ng WF, Duggan PJ, Ponchel F, Matarese G, Lombardi G, Edwards A, Issacs J, Lechler RI (2001) Human CD4(+)CD25(+) cells: a naturally occurring population of regulatory T cells. Blood 98:2736–2744
3. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M (1995) Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 155:1151–1164
4. Dieckmann D, Plottner H, Berchtold S, Berger T, Schuler G (2001) Ex vivo isolation and characterization of CD4(+)CD25(+) T cells with regulatory properties from human blood. J Exp Med 193:1303–1310
5. Asano M, Toda M, Sakaguchi N, Sakaguchi S (1996) Autoimmune disease as a consequence of developmental abnormality of a T cell subpopulation. J Exp Med 184:387–396
6. Sakaguchi S, Sakaguchi N, Shimizu J, Yamazaki S, Sakihama T, Itoh M, Kuniyasu Y, Nomura T, Toda M, Takahashi T (2001) Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev 182:18–32
7. Weiner HL (2001) Induction and mechanism of action of transforming growth factor-beta-secreting Th3 regulatory cells. Immunol Rev 182:207–214
8. Groux H, O'Garra A, Bigler M (1997) A CD4+T cells subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 389:737–742
9. Thomason AM, Shevach EM (1998) CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med 188:287–296
10. Thomason AM, Shevach EM (2000) Suppressor effector function of CD4+25+immunoregulatory T cells is antigen nonspecific. J Immunol 164:183–190
11. Takahashi T, Tagami T, Yamazaki S, Ueda T, Shimizu J, Sakaguchi N, Mak TW, Sakaguchi S (2000) Immunologic self-tolerance maintained by CD25+CD4+ regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J Exp Med 192:303–310
12. Sakaguchi S (2000) Regulatory T cells: key controllers of immunologic self-tolerance. Cell 101:455–458
13. Shevach EM (2001) Certified professionals: CD4+CD25+ suppressor T cells. J Exp Med 193:F41–F46
14. Azuma T, Takahashi T, Kinusato A, Kitamura T, Hirai H (2003) Human CD4+25+ regulatory T cells suppress NKT cells functions. Cancer Res 63:4516–4520
15. Baecher-Allan C, Viglietta V, Hafler DA (2004) Human CD4+CD25+ regulatory T cells. Semin Immunol 26:89–97
16. Baecher-Allan C, Viglietta V, Hafler DA (2002) Inhibition of human CD4(+)CD25(+high) regulatory T cell function. J Immunol 169:6210–6217
17. Baecher-Allan C, Wolf E, Hafler DA (2005) Functional analysis of highly defined, FACS-isolated populations of human regulatory CD4+ CD25+ T cells. Clin Immunol 115:10–8
18. Ichihara F, Kono K, Takahashi A, Kawaida H, Sugai H, Fujii H (2003) Increased populations of regulatory T cells in peripheral blood and tumo-infiltrating lymphocytes in patient with gastric and esophageal cancers. Clin Cancer Res 9:4404–4408
19. Wolf AM, Wolf D, Steurer M, Gastl G, Gunsilius E, Grubeck-Loebenstein B (2003) Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res 9:606–612
20. Sasada T, Kimura M, Yoshida Y, Kanai M, Takabayashi A (2003) CD4+CD25+ regulatory T cells in patients with gastrointestinal malignancies: possible involvement of regulatory T cells in disease progression. Cancer 98:1089–1099
21. Liyanage UK, Moore TT, Joo HG, Tanaka Y, Herrmann V, Doherty G, Drebin JA, Strasberg SM, Eberlein TJ, Goedegebuure PS, Linehan DC (2002) Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 169:2756–2761
22. Woo EY, Chu CS, Goletz TJ, Schlienger K, Yeh H, Coukos G, Rubin SC, Kaiser LR, June CH (2001) Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res 61:4766–4773
23. Woo EY, Yeh H, Chu CS, Schlienger K, Carroll RG, Riley JL, Kaiser LR, June CH (2002) Cutting edge: regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J Immunol 168:4272–4276
24. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, Zhu Y, Wei S, Kryczek I, Daniel B, Gordon A, Myers L, Lackner A, Disis ML, Knutson KL, Chen L, Zou W (2004) Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10:942–949
25. Kawaida H, Kono K, Takahashi A, Sugai A, Mimura K, Miyagawa N, Omata H, Kumamoto H, Ooi A, Fujii H (2005) Distribution of regulatory T cells in tumor-draining lymph nodes in patients with gastric cancer. J Surg Res 124:151–157
26. Baecher-Allan C, Brown JA, Freeman GJ, Hafler DA (2001) CD4+CD25 high regulatory cells in human peripheral blood. J Immunol 167:1245–1253
27. Levings MK, Sangregorio R, Sartirana C, Moschin AL, Battaglia M, Orban PC, Roncarolo MG (2002) Human CD25+CD4+ T suppressor cell clones produce transforming growth factor beta, but not interleukin 10, and are distinct from type 1 T regulatory cells. J Exp Med 196:1335–1346
28. Kono K, Takahashi A, Ichihara F, Amemiya H, Iizuka H, Fujii H, Sekikawa T, Matsumoto Y (2002) Prognostic significance of adoptive immunotherapy with tumor-associated lymphocytes in patients with advanced gastric cancer: a randomized trial. Clin Cancer Res 8:1767–1771
29. Kono K, Takahashi A, Sugai H, Fujii H, Choudhury AR, Kiessling R, Matsumoto Y (2002) Dendritic cells pulsed with HER-2/neu-derived peptides can induce specific T cell responses in patients with gastric cancer. Clin Cancer Res 8:3394–3400
30. Sutmuller RP, van Duivenvoorde LM, van Elsas A, Schumacher TN, Wildenberg ME, Allison JP, Toes RE, Offringa R, Melief CJ (2001) Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25+ regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J Exp Med 194:823–832

Int. J. Cancer: 118, 1173–1180 (2006)
© 2005 Wiley-Liss, Inc.

EGFR protein overexpression and gene amplification in squamous cell carcinomas of the esophagus

Mitsuhiko Hanawa[1,2], Shioto Suzuki[1], Yoh Dobashi[1], Tetsu Yamane[1], Koji Kono[3], Nobuyuki Enomoto[2] and Akishi Ooi[1*]
[1]*Department of Pathology, School of Medicine, University of Yamanashi, Japan*
[2]*Department of Internal Medicine, School of Medicine, University of Yamanashi, Japan*
[3]*Department of Surgery, School of Medicine, University of Yamanashi, Japan*

Overexpression of epidermal growth factor receptor (EGFR) is observed in many cancers, sometimes accompanied by gene amplification. Recently, several clinical therapies targeting EGFR were developed, but the eligibility criteria for these therapies is not fully established. To develop such eligibility criteria for esophageal squamous cell carcinoma (ESCC), we sought to clarify: (*i*) the exact frequency of EGFR overexpression, (*ii*) the relationship between protein overexpression and gene amplification, (*iii*) the relationship between gene amplification and specific gene mutations and (*iv*) the correlation between the status of *EGFR* and clinical or pathological features. Immunohistochemistry revealed that EGFR protein is overexpressed in 53 (50%) of the 106 ESCC examined. Fluorescence *in situ* hybridization (FISH) indicated clear *EGFR* gene amplification in 15 of the 53 tumors, somewhat higher *EGFR* copy in 32 cases, and no increase in 6 cases. Gene amplification was significantly associated with high level overexpression. Direct sequencing of exons 19 and 21 of *EGFR* revealed no mutations in 15 tumors exhibiting gene amplification, and no mutations in 25 tumors not exhibiting gene amplification. Overexpression of EGFR was significantly correlated with depth of invasion of the tumor.In conclusion, anti-EGFR therapies may be appropriate for patients with ESCC. We assume that combined analyses by immunohistochemistry/FISH would clarify aberrations in protein and gene function, and could help to identify those patients who may benefit from anti-EGFR therapy.
© 2005 Wiley-Liss, Inc.

Key words: *EGFR*; FISH; esophageal squamous cell carcinomas; immunohistochemistry; *EGFR*-targeted therapy

Esophageal cancer is the sixth most frequent cause of cancer death worldwide in 1990,[1] and squamous cell carcinoma is the predominant histologic type. The prognosis of esophageal squamous cell carcinoma (ESCC) is poor, with 5-year survival rates of about 10%, as reported by various cancer registries. Cure is expected only for superficial cancers.[2] In the future, we may be able to improve the prognoses of patients with these diseases and provide more appropriate therapies if we better understand the molecular genetic characteristics of each tumor. This may ultimately be as important as early diagnosis and effective treatment.

The epidermal growth factor receptor (*EGFR*) gene, located on chromosome 7p12, encodes a 170 kDa membrane glycoprotein. Upon activation by specific ligands such as EGF, its intrinsic kinase is activated and initiates a number of signaling pathways. In addition to being implicated in organ morphogenesis, maintenance and repair, upregulated EGFR signaling has been correlated in a wide variety of tumors with progression to invasion and metastasis.[3] *EGFR* was purified initially from the human squamous cell carcinoma cell line A431,[4] which overexpresses EGFR from 2- to 100-fold, resulting from a commensurate 3- to 110-fold increase in *EGFR* gene copy number.[5] Since then, many types of epithelial malignancies, including esophageal cancers, have been shown to express increased levels of EGFR expression on the cell membrane, with or without gene amplification.[6]

There have been several immunohistochemical (IHC) studies examining EGFR protein expression in ESCC; however, there is no consensus with regards to general frequencies of overexpression, distribution of overexpressing cells, or levels of expression.[7,8] Early studies, although small in scale, were able to quantify gene amplification and overexpression using combined Southern blot and ^{125}I-EGF binding assays: Hunts *et al.*[9] and Ozawa *et al.*[10] examined 10 and 32 ESCC tumors, respectively, and found a tumor exhibiting *EGFR* amplification as high as that in A431, with a 30-fold higher concentration of EGF binding sites than adjacent normal tissue.

Using a fluorescence *in situ* hybridization (FISH) technique combined with IHC, we have demonstrated that the major mechanism of EGFR overexpression, especially high level overexpression, in gastric,[11] colorectal,[12] pulmonary[13] and bile duct carcinomas,[14] as well as soft tissue sarcomas[15] is gene amplification. However, we also found another group in which low level overexpression occurred without gene amplification.[12–15] This led us to speculate that there may be 2 different mechanisms of EGFR overexpression: gene amplification and transcriptional/translational enhancement. We believe that detection of gene amplification by FISH may be the best method for elucidating the mechanisms of overexpression in cancers. However, there has been no study to date using this technique to detect *EGFR* aberrations in ESCC.

EGFR has recently attracted much attention because of the development of clinical therapies that target this receptor. IMC-C225 (cetuximab or Erbitux™, ImClone Systems, Branchburg, NJ), a monoclonal antibody against EGFR, is now approved for use in patients with colorectal cancers (FDA News, February 12, 2004). Among the various small molecule inhibitors of tyrosine kinases, gefitinib (ZD1839, Iressa™, AstraZeneca, Macclesfield, United Kingdom) has progressed to approval for clinical use in the USA for patients with non-small-cell lung cancer (NSCLC).

Our aim in the present study was to provide some rationale for the introduction of new adjuvant therapies for ESCC patients. First, we sought to determine the exact frequency of EGFR overexpression; second, to examine the relationship between protein overexpression and gene amplification; and third, to understand the relationship between gene amplification and gene mutation and, finally to clarify the correlation between the status of the *EGFR* gene and clinical or pathological features of the tumors.

Material and methods

Tissue samples

We examined 106 cases of ESCC and concurrently excised nodal metastases obtained from consecutive surgeries performed

Abbreviations: AJCC, American Joint Committee on Cancer; COX-2, cyclooxygenase-2; DM, double minute chromosomes; EGF, epidermal growth factor; EGFR, epidermal growth factor receptor; ESCC, esophageal squamous cell carcinoma; FISH, fluorescence *in situ* hybridization; HSR, homogeneously staining regions; IHC, immunohistochemical; LA/Poly, low amplification/polysomy; NSCLC, non-small-cell lung cancer.

Grant sponsor: The Japanese Ministry of Education, Sports, Science and Culture; Grant numbers: C 15590298 (AO), C 16590272 (YD); Grant sponsor: Yamanashi Academy of Science.
***Correspondence to:** Department of Molecular and Cellular Pathology, Kanazawa University Graduate School of Medical Science, 13-1 Takara-machi, Kanazawa, Ishikawa 920-8640, Japan. Fax: +81-76-234-4228. E-mail: aooi@med.kanazawa-u.ac.jp
Received 6 December 2004; Accepted after revision 15 June 2005
DOI 10.1002/ijc.21454
Published online 13 September 2005 in Wiley InterScience (www.interscience.wiley.com).

at the Department of Surgery, University of Yamanashi between 1987 and 2004. The patients consisted of 97 men and 9 women, with a median age of 63 years (mean, 63.7; SD, 7.6; range, 43–80). Patients who had received irradiation and/or chemotherapy before surgery were excluded. The World Health Organization Classification of Tumors was used histologically to grade cases of ESCC.[2] The condition of the patients was assessed according to the system for staging primary tumor/regional lymph nodes/distant metastasis (TNM) described in the American Joint Committee on Cancer Staging Manual.[16] The 106 patients were classified into the TNM stages as follows: Stage 0, 2 patients; Stage I, 21 patients; Stage IIA, 33 patients; Stage IIB, 15 patients; Stage III, 32 patients and Stage IV, 3 patients. This laboratory study was approved by the Institutional Review Board at the University of Yamanashi, and written informed consent was obtained.

Immunohistochemistry (IHC)

Resected esophageal samples were immediately immersed in 20% buffered neutral formalin, fixed overnight and embedded in paraffin according to standard procedures. 1 or more representative blocks in which the carcinoma showed the deepest extent of invasion was used for histological analyses for each case. Serial sections (4 μm) were cut from representative formalin-fixed, paraffin-embedded cancer tissues, placed onto silanated glass slides and subjected to hematoxylin-eosin staining, EGFR IHC analysis and FISH analysis. IHC detection of EGFR was carried out on all primary tumors, as well as metastatic tumors of the lymph nodes, using a monoclonal antibody against the external domain of human EGFR (Novocastra Lab, Newcastle, UK; Working dilution, 1:20). The specificity and sensitivity of this antibody against EGFR were verified previously.[11,12] For IHC detection, a high-temperature antigen unmasking technique was used: *i.e.*, the section was autoclaved in 0.01 M citrate buffer (pH 7.0) at 121°C for 10 min. Antibody was visualized by avidin-biotin binding to peroxidase-conjugated secondary antibodies. In each analysis, a colon cancer section that had been previously confirmed to overexpress EGFR[12] was included as a positive control.

EGFR positivity in the IHC analyses was reviewed by 3 pathologists (MH, SS, YD), who were unaware of the gene amplification status of the sample. The intensity of reactivity was scored using a four-tier system, which we have established in previous studies on EGFR expression: negative, no discernible staining or background type staining; 1+, definite cytoplasmic staining and/or equivocal discontinuous membrane staining; 2+, unequivocal membrane staining with moderate intensity; 3+ strong and complete plasma membrane staining.[11–13] Samples exhibiting 2+ or 3+ immunostaining were classified as "overexpression", since we have previously demonstrated that only cases showing 2+ or 3+ positivity in IHC by our criteria were frequently associated with gene amplification of *EGFR*.[11–13,15] The extent (%) of positive staining cells was measured in a representative large section of each tumor.

FISH analysis

FISH analysis was undertaken for all cases of primary tumors exhibiting 3+ or 2+ staining (53 cases), and for another 20 representative tumors exhibiting 1+ staining. In addition, 10 tumors that scored negative for EGFR were selected at random as negative controls. Metastatic nodes from the primary tumors exhibiting gene amplification were also examined. Gene amplification of *EGFR* (7p12) was determined using a DNA probe set (LSI™ EGFR/CEP™ 7; Vysis, Downers Grove, IL) consisting of a SpectrumOrange™-labeled *EGFR* (locus)-specific probe and a SpectrumGreen™-labeled probe that hybridizes to the centromeric region of chromosome 7. The latter probe was used as the control to normalize copy number for chromosome 7. FISH was performed using standard methods, with a modification to incorporate an intermittent, short-term microwave treatment during the initial period of hybridization as described earlier.[12,17] The tissue sections were counterstained with 4′,6-diamidine-2′-phenylindole dihydrochloride and p-phenylenediamine in phosphate-buffered saline and glycerol (DAPI II) (Vysis) and examined under a fluorescence microscope (Olympus, Tokyo, Japan). The microscope was equipped with a Triple Bandpass Filter set (Vysis) to discriminate DAPI II, SpectrumOrange™ and SpectrumGreen™, as well as filter sets specific for SpectrumOrange and SpectrumGreen. As positive controls, colon cancer tissues that had been previously confirmed to have *EGFR* gene amplification were used.[12] The number of *EGFR* signals and centromere 7 signals in the nucleus of cancer cells were counted and evaluated as follows. Basically, a cell in which the number of *EGFR* signals was greater than the number of centromere 7 signals was interpreted as positive for amplification. Among these, i) a cell with a definite cluster of *EGFR* signals or a total of more than 10 *EGFR* signals was scored as exhibiting high-level amplification[11–13,15] and ii) a cell with 3–10 *EGFR* signals was scored as low-level amplification. In addition, a cell in which both centromeric and *EGFR* signals were equally increased was scored as polysomic.[18] FISH images were taken using a photographic camera and recorded on film slides.

Direct sequencing of exons 19 and 21 of the EGFR *gene*

To clarify the possible relationship between gene amplification and specific mutations in *EGFR*, we performed direct sequencing. Given the apparent clustering of *EGFR* mutations in gefinitib-sensitive non-small-cell lung carcinoma,[19,20] we sequenced only exons 19 and 21 in 40 primary tumors, consisting of 15 tumors with gene amplification and 25 tumors without amplification. DNA was extracted from 40 paraffin-embedded tumors (15 tumors with amplification and 25 without amplification) using DEXPAT™ (TaKaRa, Kyoto, Japan). DNA was also extracted from 9 tumors (2 with amplification and 7 without amplification) by phenol and chloroform, in which fresh surgical tissues could be obtained. The polymerase chain reaction (PCR) was used to amplify exons 19 and 21 according to a previous report by Lynch *et al.*[19] Primer pairs used for the amplification were as follows: Exon 19, GCAATATCAGCCTTAGGTG-CGGCTC (sense) and CATAGAAAGTGAACATTTAGGATGTG (antisense), and Exon 21, CTAACGTTCGCCAGCCATAAGTCC (sense) and GCTGCGAGCTCACCCAGAATGTCTGG (antisense). For the amplification of DNA extracted from paraffin-embedded tumor tissues, nested PCR amplification was performed as follows. An initial PCR product was generated using primers described earlier. Subsequently, 2 μl of this reaction was amplified in a secondary PCR, using the following internal primer pairs; Exon 19, CC TTAGGTGCGGCTCCACAGC (sense) and CATTTAGGATGTG GAGATGAGC (antisense); Exon 21, CAGCCATAAGTCCTCGA CGTGG (sense) and CATCCTCCCCTGCATGTGTTAAAC (antisense). In both reactions, the annealing temperature was 58°C. The PCR amplicon was purified using SUPREC™ (TaKaRa, Kyoto, Japan). Purified DNA was cycle-sequenced using the ABI BigDye Termination kit v1.1 (ABI, Foster City, CA) according to manufacturer's instructions. Sequence reactions were electrophoresed on an ABI 3730xl DNA analyzer. Electrophoregrams were analyzed in both the sense and antisense directions and compared with the *EGFR* sequence deposited in the GenBank data base, Access No. AY588246 for the presence of mutations.

Statistical analysis

Agreement among observers in their interpretation of IHC specimens was tested by kappa (κ) statistics.[21] In accordance with the criteria of Landis and Koch,[22] the κ values were divided into several scales to evaluate the strength of the agreement: $\kappa < 0.00$, poor; $0.00 < \kappa < 0.20$, slight; $0.21 < \kappa < 0.40$, fair; $0.41 < \kappa < 0.60$, moderate; $0.61 < \kappa < 0.80$, substantial; $0.81 < \kappa < 1.00$, nearly perfect. A χ^2 test for independence was used to examine the correlation among the status of EGFR protein, gene and the several clinicopathological factors. Patients' survival was analyzed by the Kaplan-Meier method, with Logrank test for univariate analysis.



FIGURE 1 – Infiltrating squamous cell carcinoma of the esophagus. (*a*) 3+ immunostaining cells are localized to a tumor nest. (50×) (*b*) FISH analysis shows clusters of orange signals in cancer nuclei corresponding to the *EGFR* gene (320×).



FIGURE 2 – T1 tumor. (*a*) 3+ immunostaining cells are localized to mucosal cancer (50×). (*b*) FISH analysis on the adjacent section shows 3+ immunostaining cells with clustered *EGFR* signals (50×). (*c*) Higher magnification of B (250×).

Results

EGFR *protein expression*

Overexpression of EGFR (2+ and 3+ staining) was exclusively confined to cancer cells. Some focal staining was present in basal cells and parabasal cells in normal esophageal epithelium; however, their intensities did not exceed 1+ staining.

Among the 106 ESCC cases analyzed, overexpression of EGFR was found in 53 cases (50%), of which 18 cases scored 3+ for EGFR staining and 35 cases scored 2+ staining. Low level (1+) immunoreactivity similar in intensity to the basal cell of normal esophageal mucosa was found in 41 tumors (39%), and these were scored as not overexpressing EGFR protein. No EGFR immunoreactivity was detected in 12 (11%) of the tumors. Although overall